Article Details
Retrieved on: 2022-05-12 19:48:25
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of ...
Article found on: www.zacks.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here